NCT07201714RecruitingEarly phase 1
Oral Carnitine in Heart Failure Patients
Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 20 Jun 2025
- Start date
- 12 Nov 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Diseases
- Heart failure
- NCT number
- NCT07201714
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 12 Nov 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently undergoing renal replacement therapy of any kind
Other illness
- History of seizures of any type
Lab values
- Estimated GFR \<15 mL/min/1.73m2 or Stage 5 chronic kidney disease
- Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
Other
- Pregnant, breastfeeding or intending pregnancy
- Unable to provide consent
Who the study is looking for
- Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
- Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
- Age ≥ 18 years
- Able to speak and read English
- Willing and able to provide consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.